Patent Assignment Agreement Sample Contracts

Marizyme Inc – PATENT ASSIGNMENT AGREEMENT (September 12th, 2018)

THIS PATENT PURCHASE AND ASSIGNMENT AGREEMENT (the “Agreement”) is dated as of September 12th, 2018, by and between ACB Holding AB, Reg. No. 559119-5762 a Sweden company, with an address at Kraftriket 11B, 114 19 Stockholm, Sweden (“Assignor”) and Marizyme, Inc., a Nevada corporation formerly known as GBS Enterprises Incorporated, with an address at 2295 Towne Lake Parkway Suite 116-290 Woodstock, GA 30189 (the “Assignee”).

BeiGene, Ltd. – RISK FACTORS An [REDACTED] in our ordinary shares and/or ADSs involves significant risks. You should carefully consider all of the information in this [REDACTED], including the risks and uncertainties described below, as well as our financial statements and the related notes, and the “Financial Information” section, before deciding to [REDACTED] in our ordinary shares and/or ADSs. The following is a description of what we consider to be our material risks. Any of the following risks could have a material adverse effect on our business, financial condition, results of operations and growth pros (July 24th, 2018)
Pineapple Express, Inc. – PATENT ASSIGNMENT AGREEMENT (January 23rd, 2018)

This Patent Assignment Agreement (“Agreement”) is made and entered into as of the 20 day of JULY, 2016, by and between SKY ISLAND, INC.., a California corporation, whose principal business address is 6700 Foolproof Avenue, Suite 289, West Hills, California 91307 (hereafter “Assignor”); and PINEAPPLE EXPRESS, INC., a Wyoming corporation whose principal business address is 10351 Santa Monica Blvd., Suite 420, Century City, California 90067 (hereafter “Assignee”).

Quantrx Biomedical Corp – PATENT ASSIGNMENT AGREEMENT (December 21st, 2017)

This PATENT ASSIGNMENT AGREEMENT (“Agreement”) is made as of December 14, 2017, by and between QuantRx Biomedical Corporation, a Nevada corporation (“Assignor”), and Preprogen LLC, a Delaware limited liability company (“Assignee”).

Accurexa Inc. – PATENT ASSIGNMENT AGREEMENT (July 10th, 2017)

THIS PATENT ASSIGNMENT AGREEMENT (the “Agreement”) is signed by the following Parties and is effective as of 7th July, 2017 (the “Effective Date”):

FORM Holdings Corp. – CONFIDENTIAL SETTLEMENT AND PATENT ASSIGNMENT AGREEMENT (March 30th, 2017)

This CONFIDENTIAL SETTLEMENT AND PATENT ASSIGNMENT AGREEMENT (this “Agreement”) is entered into on December 5, 2016 (the “Effective Date”), by and between FORM Holdings Corp., a Delaware corporation formerly known as Vringo Inc (“FORM Holdings”) and Nokia Corporation, a company organized under the laws of Finland (“Nokia”). FORM Holdings and Nokia are herein referred to separately as “a party” or collectively as “the parties.”

Vivus Inc – PATENT ASSIGNMENT AGREEMENT (March 8th, 2017)

This Patent Assignment Agreement is entered into as of the Effective Date (as defined below), by and between Selten Pharma, Inc., a Cayman Islands company, having a principal place of business at 751 Laurel St, #520, San Carlos, CA 94070, (“SELTEN”) and VIVUS, Inc., a Delaware company having a principal place of business at 900 E. Hamilton Ave., Suite 550,  Campbell, California 95008 (“VIVUS”).

CRISPR Therapeutics AG – PATENT ASSIGNMENT AGREEMENT (October 7th, 2016)

THIS PATENT ASSIGNMENT AGREEMENT (“Agreement”) is entered into and effective as of 7th November 2014 (the “Effective Date”), by and between EMMANUELLE MARIE CHARPENTIER, an individual residing at Böcklerstrasse 18, 38102 Braunschweig, Germany (“Ms Charpentier”), THE UNIVERSITY OF VIENNA, having a principal place of business at Universitätsring 1, 1010 Vienna, Austria (“Vienna”), and Ines Fonfara, an individual residing at Helmstedter Strasse 144, 38102 Braunschweig, Germany (“Ms Fonfara”) (collectively “Assignor”), and CRISPR THERAPEUTICS AG, a company organized under the laws of Switzerland having a principal place of business at Aeschenvorstadt 36, CH-4051 Basel, Switzerland (“Assignee”).

CRISPR Therapeutics AG – PATENT ASSIGNMENT AGREEMENT (August 19th, 2016)

THIS PATENT ASSIGNMENT AGREEMENT (“Agreement”) is entered into and effective as of 7th November 2014 (the “Effective Date”), by and between EMMANUELLE MARIE CHARPENTIER, an individual residing at Böcklerstrasse 18, 38102 Braunschweig, Germany (“Ms Charpentier”), THE UNIVERSITY OF VIENNA, having a principal place of business at Universitätsring 1, 1010 Vienna, Austria (“Vienna”), and Ines Fonfara, an individual residing at Helmstedter Strasse 144, 38102 Braunschweig, Germany (“Ms Fonfara”) (collectively “Assignor”), and CRISPR THERAPEUTICS AG, a company organized under the laws of Switzerland having a principal place of business at Aeschenvorstadt 36, CH-4051 Basel, Switzerland (“Assignee”).

Accurexa Inc. – PATENT ASSIGNMENT AGREEMENT (July 22nd, 2016)
CRISPR Therapeutics AG – PATENT ASSIGNMENT AGREEMENT (July 8th, 2016)

THIS PATENT ASSIGNMENT AGREEMENT (“Agreement”) is entered into and effective as of 7th November 2014 (the “Effective Date”), by and between EMMANUELLE MARIE CHARPENTIER, an individual residing at Böcklerstrasse 18, 38102 Braunschweig, Germany (“Ms Charpentier”), THE UNIVERSITY OF VIENNA, having a principal place of business at Universitätsring 1, 1010 Vienna, Austria (“Vienna”), and Ines Fonfara, an individual residing at Helmstedter Strasse 144, 38102 Braunschweig, Germany (“Ms Fonfara”) (collectively “Assignor”), and CRISPR THERAPEUTICS AG, a company organized under the laws of Switzerland having a principal place of business at Aeschenvorstadt 36, CH-4051 Basel, Switzerland (“Assignee”).

Helpful Alliance Co – PATENT ASSIGNMENT AGREEMENT (January 11th, 2016)

THIS PATENT ASSIGNMENT AGREEMENT (this “Agreement”) is entered into on March 18, 2014 by and between HELPFUL ALLIANCE COMPANY INC. (hereinafter referred to as the “Assignor”), a Florida Corporation having a principal address at 3732 SW 30th Ave, Ste. 202, Fort Lauderdale, and

Concert Pharmaceuticals, Inc. – PATENT ASSIGNMENT AGREEMENT (May 11th, 2015)

This PATENT ASSIGNMENT AGREEMENT (this “Agreement”) is entered into as of September 8, 2011 (the “Effective Date”) by and between AUSPEX PHARMACEUTICALS, INC., a Delaware corporation with its registered office at 3366 North Torrey Pines Court, Suite 225, La Jolla, California, 92037 (“Auspex”), and CONCERT PHARMACEUTICALS, INC., a Delaware corporation, with its registered office at 99 Hayden Avenue, Suite 500, Lexington, MA 02421 (“Concert”). Auspex and Concert are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.

S&W Seed Co – PATENT ASSIGNMENT AGREEMENT (January 7th, 2015)

This Patent Assignment Agreement (this "Agreement") is made as of the 31st day of December, 2014 (the "Effective Date"), by and between Pioneer Hi-Bred International, Inc., an Iowa corporation with a principal place of business at 7100 N.W. 62nd Avenue, Johnston, IA 50131, USA ("Seller") and S&W Seed Company, a Nevada Corporation with a principal place of business at 25552 South Butte Avenue, Five Points, California 93624 ("Buyer"). Unless otherwise defined herein, capitalized terms shall have the meaning ascribed to them in that certain Asset Purchase and Sale Agreement dated as of December 19, 2014 by and between Seller and Buyer (the "APSA").

ITUS Corp – PATENT ASSIGNMENT AGREEMENT (January 5th, 2015)

This Patent Assignment Agreement (the "Agreement"), effective as of the date that it is signed by the last party to sign it as indicated on the signature page (the "Effective Date") is made by and between ITUS Corporation, formerly known as CopyTele, Inc., having a principal place of business at 900 Walt Whitman Road, 2nd Floor, Melville, New York 11747 ("ITUS"), and AU Optronics Corporation, having a principal place of business at No. 1, Li-Hsin Rd. 2, Hsinchu Science Park, Hsinchu 30078, Taiwan, Republic of China ("AUO") (collectively, the "Parties" or either individually, a "Party").

Flex Pharma, Inc. – PATENT ASSIGNMENT AGREEMENT (December 29th, 2014)

This PATENT ASSIGNMENT AGREEMENT is dated as of March 20, 2014 (this “Assignment”), by RODERICK MACKINNON, DONALD MACKINNON, and BRUCE BEAN, individuals residing at 504 East 63rd Street, Apt 33M, New York, NY 10065, 305 East 85th St. Apt 17A, New York, NY 10028, and 20 Locke Road, Waban, MA 02468 respectively (collectively “Assignors”), and FLEX PHARMA, INC., with offices at Prudential Tower, 800 Boylston Street, c/o Longwood Fund, Boston, MA 02199 (“Assignee”).

Flex Pharma, Inc. – PATENT ASSIGNMENT AGREEMENT (December 8th, 2014)

This PATENT ASSIGNMENT AGREEMENT is dated as of March 20, 2014 (this “Assignment”), by RODERICK MACKINNON, DONALD MACKINNON, and BRUCE BEAN, individuals residing at 504 East 63rd Street, Apt 33M, New York, NY 10065, 305 East 85th St. Apt 17A, New York, NY 10028, and 20 Locke Road, Waban, MA 02468 respectively (collectively “Assignors”), and FLEX PHARMA, INC., with offices at Prudential Tower, 800 Boylston Street, c/o Longwood Fund, Boston, MA 02199 (“Assignee”).

Vivus Inc – PATENT ASSIGNMENT AGREEMENT (November 5th, 2014)

This Patent Assignment Agreement is entered into as of the Execution Date (as defined below), by and between Janssen Pharmaceuticals, Inc., a Pennsylvania company having a principal place of business at 1125 Trenton-Harbourton Road, Titusville, New Jersey 08560 (“JANSSEN”) and VIVUS, Inc., a Delaware company having a principal place of business at 351 E. Evelyn Ave., Mountain View, California 94041 (“VIVUS”).

Endostim, Inc. – PATENT ASSIGNMENT AGREEMENT (September 5th, 2014)

This PATENT ASSIGNMENT AGREEMENT (this “Agreement”), is made and entered into as of the 15th day of December, 2009 (the “Effective Date”), by and between Edy E. Soffer, an individual residing at #### ###### ######, ###########, ########## ##### (“Dr. Soffer”) and Jeffrey Conklin, an individual residing at ### ############## ###########, ## ##### (“Dr. Conklin”) and EndoStim, Inc., a Delaware corporation (“EndoStim”).

Endostim, Inc. – PATENT ASSIGNMENT AGREEMENT (September 5th, 2014)

This Patent Assignment Agreement (“Agreement”) is entered into as of September 2, 2009 (“Effective Date”) by and among VIRENDER SHARMA, M.D. (“Dr. Sharma”) and SARAH M. SHARMA (“Sarah Sharma”), husband and wife and both of whom being Arizona residents (together “Assignor”), ENDOSTIM, INC., a Delaware corporation (“Assignee”), and ENDOSTIM, INC., an Arizona corporation (“EndoStim Arizona”). EndoStim Arizona is a party to this Agreement only for the purpose set forth in Section 3.3 of this Agreement.

Endostim, Inc. – AMENDMENT NO. 1 TO PATENT ASSIGNMENT AGREEMENT (September 5th, 2014)

THIS AMENDMENT NO. 1 TO PATENT ASSIGNMENT AGREEMENT (this “Amendment”) is made and entered into this 11th day of January, 2010 (the “Effective Date”), by and among VIRENDER SHARMA, M.D. (“Dr. Sharma”) and SARAH M. SHARMA (“Sarah Sharma”), husband and wife and both of whom being Arizona residents (together “Assignor”), ENDOSTIM, INC., a Delaware corporation (“Assignee”) and ENDOSTIM, INC., an Arizona corporation (“EndoStim Arizona”). EndoStim Arizona is only a party to this Amendment to confirm that it has no ownership or other interest, however defined or classified, in any Intellectual Property or Patent Assets.

Endostim, Inc. – PATENT ASSIGNMENT AGREEMENT (July 21st, 2014)

This PATENT ASSIGNMENT AGREEMENT (this “Agreement”), is made and entered into as of the 15th day of December, 2009 (the “Effective Date”), by and between Edy E. Soffer, an individual residing at #### ###### ######, ###########, ########## ##### (“Dr. Soffer”) and Jeffrey Conklin, an individual residing at ### ############## ###########, ## ##### (“Dr. Conklin”) and EndoStim, Inc., a Delaware corporation (“EndoStim”).

Endostim, Inc. – PATENT ASSIGNMENT AGREEMENT (July 21st, 2014)

This Patent Assignment Agreement (“Agreement”) is entered into as of September 2, 2009 (“Effective Date”) by and among VIRENDER SHARMA, M.D. (“Dr. Sharma”) and SARAH M. SHARMA (“Sarah Sharma”), husband and wife and both of whom being Arizona residents (together “Assignor”), ENDOSTIM, INC., a Delaware corporation (“Assignee”), and ENDOSTIM, INC., an Arizona corporation (“EndoStim Arizona”). EndoStim Arizona is a party to this Agreement only for the purpose set forth in Section 3.3 of this Agreement.

Endostim, Inc. – AMENDMENT NO. 1 TO PATENT ASSIGNMENT AGREEMENT (July 21st, 2014)

THIS AMENDMENT NO. 1 TO PATENT ASSIGNMENT AGREEMENT (this “Amendment”) is made and entered into this 11th day of January, 2010 (the “Effective Date”), by and among VIRENDER SHARMA, M.D. (“Dr. Sharma”) and SARAH M. SHARMA (“Sarah Sharma”), husband and wife and both of whom being Arizona residents (together “Assignor”), ENDOSTIM, INC., a Delaware corporation (“Assignee”) and ENDOSTIM, INC., an Arizona corporation (“EndoStim Arizona”). EndoStim Arizona is only a party to this Amendment to confirm that it has no ownership or other interest, however defined or classified, in any Intellectual Property or Patent Assets.

Auspex Pharmaceuticals, Inc. – PATENT ASSIGNMENT AGREEMENT (December 20th, 2013)

This PATENT ASSIGNMENT AGREEMENT (this “Agreement”) is entered into as of September 8, 2011 (the “Effective Date”) by and between AUSPEX PHARMACEUTICALS, INC., a Delaware corporation with its registered office at 3366 North Torrey Pines Court, Suite 225, La Jolla, California, 92037 (“Auspex”), and CONCERT PHARMACEUTICALS, INC., a Delaware corporation, with its registered office at 99 Hayden Avenue, Suite 500, Lexington, MA 02421 (“Concert”). Auspex and Concert are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.

Auspex Pharmaceuticals, Inc. – PATENT ASSIGNMENT AGREEMENT (November 21st, 2013)

This PATENT ASSIGNMENT AGREEMENT (this “Agreement”) is entered into as of September 8, 2011 (the “Effective Date”) by and between AUSPEX PHARMACEUTICALS, INC., a Delaware corporation with its registered office at 3366 North Torrey Pines Court, Suite 225, La Jolla, California, 92037 (“Auspex”), and CONCERT PHARMACEUTICALS, INC., a Delaware corporation, with its registered office at 99 Hayden Avenue, Suite 500, Lexington, MA 02421 (“Concert”). Auspex and Concert are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.

Omeros Corp – FIRST AMENDMENT TO PATENT ASSIGNMENT AGREEMENT (March 18th, 2013)

This first amendment (the “Amendment”) effective 31 December 2010 is made to the patent assignment dated the 23rd day of February 2009 (the “Assignment Agreement”) between Omeros Corporation, a Washington corporation having a principal place of business at 1420 Fifth Avenue, Suite 2600, Seattle WA 98101 USA (“Omeros”) and Roberto Ciccocioppo, Ph.D., having a residence at Vicolo San Silvestro n. 25, Camerino, 62032 IT (“Dr. Ciccocioppo”).

Poly Shield Technologies Inc. – EUROPEAN PATENT ASSIGNMENT AGREEMENT (January 17th, 2013)

THIS PATENT ASSIGNMENT AGREEMENT (the “Agreement”) is made an entered into, and is effective as of this 12th day of January, 2013, between Rasmus Norling (hereinafter the “Inventor” or “Assignor”) and Poly Shield Technologies, Inc., a corporation organized and existing under the laws of the State of Delaware (hereinafter “Poly Shield Technologies” or the “Assignee”).

NeurogesX Inc – SETTLEMENT, RELEASE AND PATENT ASSIGNMENT AGREEMENT (August 10th, 2012)

This Settlement, Release and Patent Assignment Agreement (this “Agreement”) is made as of April 3, 2012 (“Effective Date”), by and among NeurogesX, Inc., a California corporation with its principal place of business at 2215 Bridgepointe Parkway, Suite 200, San Mateo, California 94404 (“NeurogesX”), The Regents of the University of California, a California corporation having its statewide administrative offices at 1111 Franklin Street, Oakland, California 94607-5200, (the “Regents”), Marco Pappagallo (“Pappagallo”) and Peter Staats (“Staats”) (each individually, a “Party,” and collectively, the “Parties”).

Unigene Laboratories Inc – PATENT ASSIGNMENT AGREEMENT (November 9th, 2011)

THIS PATENT ASSIGNMENT AGREEMENT (the “Agreement”) is made and is effective as of September 15, 2011 (the “Effective Date”), by and between UNIGENE LABORATORIES, INC., a Delaware corporation having a place of business at 110 Little Falls Road, Fairfield, NJ 07004 (hereinafter referred to as “Company”) and KIERAN MURPHY, LLC, having its office at 100 West Road, Suite 300, Towson, MD 21210 (hereinafter referred to as “Murphy”).

Tongli Pharmaceuticals (USA), Inc. – Patent Assignment Agreement (English Translation) (July 14th, 2011)
Endocyte Inc – Patent Assignment Agreement (September 28th, 2010)

This Patent Assignment Agreement is entered into as of November 1, 2007 (the “Effective Date”), by and among Endocyte Inc., an Indiana corporation located at 3000 Kent Avenue, West Lafayette, IN 47906 (“Endocyte”); Optical Therapeutic Technologies Inc., an Indiana corporation located at 3000 Kent Avenue, West Lafayette, IN 47906 (“OTT”); and Karim N. Jallad, Michael D. Kennedy, Philip S. Low, and Dor Ben-Amotz, individuals residing at the addresses in the signature block (collectively, “Inventors”).

Quikbyte Software Inc – PATENT ASSIGNMENT AGREEMENT (September 21st, 2009)

This Patent Assignment Agreement (“Agreement”) is made as of June 10, 2009 by Henry H. Ji, an individual (“Assignor”), to Sorrento Therapeutics, Inc., a California corporation having a place of business at 10054 Mesa Ridge Court, Suite 122, San Diego, CA 92121 (“Assignee”).

Omeros Corp – PATENT ASSIGNMENT AGREEMENT (September 16th, 2009)

This agreement (the “Agreement”) is made effective the 23rd day of February 2009 (the “Effective Date”) between Omeros Corporation, a Washington corporation having a principal place of business at 1420 Fifth Avenue, Suite 2600, Seattle WA 98101 USA (“Omeros”) and Roberto Ciccocioppo, Ph.D., having a residence at Vicolo San Silvestro n. 25, Camerino, 62032 IT (“Dr. Ciccocioppo”).

Omeros Corp – PATENT ASSIGNMENT AGREEMENT (May 15th, 2009)

This agreement (the “Agreement”) is made effective the 23rd day of February 2009 (the “Effective Date”) between Omeros Corporation, a Washington corporation having a principal place of business at 1420 Fifth Avenue, Suite 2600, Seattle WA 98101 USA (“Omeros”) and Roberto Ciccocioppo, Ph.D., having a residence at Vicolo San Silvestro n. 25, Camerino, 62032 IT (“Dr. Ciccocioppo”).